Global EPLERENONE Market 2023-2030

    In Stock

    Coming Soon

    Global EPLERENONE Market



    Eplerenone, marketed under the trade name Inspra, is a potassium-saving diuretic that acts as an aldosterone antagonist and is used to treat chronic heart failure and high blood pressure, especially in people who have resistant hypertension brought on by increased aldosterone.


    It treats heart failure and lowers the chance of developing other heart issues or a stroke. It also aids in preventing the progression of heart failure. Hyperaldosteronism is a condition that it can occasionally be used to cure. When the body produces too much aldosterone, a hormone that regulates blood pressure, this occurs.Long-term treatment with eplerenone is possible.



    infographic: EPLERENONE Market , EPLERENONE Market Size, EPLERENONE Market Trends, EPLERENONE Market Forecast, EPLERENONE Market Risks, EPLERENONE Market Report, EPLERENONE Market Share.


    The Global EPLERENONE market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.



    In response to advice from the trial’s independent Executive Steering Committee, Pfizer Inc. declared that it intends to stop recruiting participants early in the EMPHASIS-HF trial.


    The recommendations come after a second interim analysis by the EMPHASIS-HF trial’s independent Data Safety Monitoring Committee, which confirmed the study’s primary effectiveness endpoint had been attained early in accordance with the protocol’s pre-defined stopping procedures.


    In comparison to patients on the placebo arm of the trial, who received standard care along with a matching placebo, the interim analysis revealed that patients treated with INSPRA® (eplerenone), in addition to current standard of care, had a significantly lower risk of cardiovascular (CV) death or heart failure (HF) hospitalisation.


    The trial’s placebo arm, where patients received standard care along with a matching placebo, saw a significant increase in the risk of cardiovascular (CV) death or heart failure (HF) hospitalisation, according to the interim analysis.


    Patients treated with INSPRA® (eplerenone), in addition to standard care, did not experience this risk. Plerenone was generally well tolerated during the EMPHASIS-HF study, according to the interim analysis performed by the independent data safety monitoring committee.


    Both hyperkalemia (elevated potassium) (8 percent in the eplerenone group vs 3% in the placebo group; p 0.001) and renal impairment (4 percent in the eplerenone group vs 2% in the placebo group; p 0.05) were listed as adverse events. Agents that act as mineralocorticoid receptor antagonists frequently cause these negative effects


    . In the double-blind, placebo-controlled, parallel group EMPHASIS-HF trial, patients with mild chronic systolic heart failure (NYHA functional Class II) and left ventricular systolic dysfunction were compared between eplerenone plus standard heart failure therapy and placebo plus standard heart failure therapy.




    1. How many EPLERENONE are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global EPLERENONE and key vendor selection criteria
    3. Where is the EPLERENONE manufactured? What is the average margin per unit?
    4. Market share of Global EPLERENONE market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global EPLERENONE in-house
    6. key predictions for next 5 years in Global EPLERENONE market
    7. Average B-2-B EPLERENONE market price in all segments
    8. Latest trends in EPLERENONE market, by every market segment
    9. The market size (both volume and value) of the EPLERENONE market in 2023-2030 and every year in between?
    10. Production breakup of EPLERENONE market, by suppliers and their OEM relationship


    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2023-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2023-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2023-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2023-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
      Your Cart
      Your cart is emptyReturn to Shop